Navigation Links
Sosei Announces Deal With UK Biotech Company
Date:10/14/2009

TOKYO, Japan, October 14 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties. Sosei had positioned the compounds for intervention in inflammatory diseases such as Inflammatory Bowel Disease (IBD). Biocopea intends to develop the portfolio of compounds further using its specialized chemical design, specific disease models and immunology expertise.

The deal means that a promising class of new chemical entities with a long remaining patent life can be taken forward by a partner committed to the development of new therapies for a variety of immune diseases. Under the terms of the assignment, Sosei will receive payments when the compounds are commercialized by Biocopea or its partners.

Notes for Editors:

About Sosei

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

About Biocopea

Biocopea is focussed upon the identification and exploitation of novel biology from existing drug templates. It is 75% owned by PepTcell Limited, a biotechnology company with the aim of converting theoretical concepts into novel analytical tools and clinical products, in the field of immunology.

For further information about Biocopea, please visit http://www.bicopea.com

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan
2. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
3. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
4. Sosei Announces Outcome of Strategy Review
5. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
6. Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care
7. Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award
8. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. Nanogea Announces New Scientific Advisory Board Members
11. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... ... 2017 , ... PRC Clinical and SDC are organizing a ... to 8:30pm EDT at Catalyst in Cambridge, MA. , Clinical operations experts ... tracking enrollment progress to communicating with underperforming sites to engaging with patient advocacy ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... announced the release of their latest product LabCODE™, a novel Lab Information ... LabCODE™ offers pre-built capabilities for Biobanking, Pharmacokinetics, Pharmacogenetics, Next Generation Sequencing, Flow ...
(Date:9/12/2017)... ... September 12, 2017 , ... September ... announce that Jeremy Nicholson, Head of the Department of Surgery and Cancer and ... 2018 Wallace H. Coulter Lecture. His presentation, “Analytical Science in Precision Medicine: ...
(Date:9/12/2017)... Cambridge (PRWEB) , ... September 11, 2017 , ... ... US offices in Cambridge, MA, announce today that Holotype HLA and other Omixon ... the annual meeting of the American Society for Histocompatibility and Immunogenetics ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):